A Phase 2 interventional study of sitagliptin phosphate and Comparator: Placebo in Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 69 Years. Per ClinicalTrials.gov, last updated 2017-05-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 109th largest by enrollment of the 197 interventional ones that give a count, is one of 4 that started in 2005, is one of 10 in phase 2, and was the 55th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 108th largest by enrollment of the 170 interventional ones that give a count, is one of 7 that started in 2005, is one of 21 in phase 2, and was the 58th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo
Drug: Comparator: Placebo
Sitagliptin 100 mg
Drug: sitagliptin phosphate
Sitagliptin 50 mg
Drug: Comparator: Sitagliptin
100 mg once daily (QD), taken orally for 4 weeks
Also known as: MK0431
Placebo tablet, QD, taken orally for 4 weeks
50 mg twice daily (BID), taken orally for 4 weeks
Also known as: MK0431
Change From Baseline in 24-hour Weighted Mean Plasma Glucose
Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.
Time frame: Baseline and Week 4
Change From Baseline in Plasma Glucose
Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0.
Time frame: Baseline and Week 4
Phase II. First patient in: 31 July 2005. Last patient, last visit: 13 February 2006. The study was conducted at 8 centers in Japan.
| Milestone | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo |
|---|---|---|---|
| Started | 27 | 25 | 28 |
| Completed | 26 | 25 | 27 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Incorrect study drug | 1 | 0 | 0 |
Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.
| mg/dL | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo |
|---|---|---|---|
| Change From Baseline in 24-hour Weighted Mean Plasma Glucose | -34.9 (-40.9 to 28.9) | -28.6 (-34.7 to 22.4) | -9.0 (-14.8 to -3.2) |
Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0.
| mg/dL | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo |
|---|---|---|---|
| Change From Baseline in Plasma Glucose | -22.3 (-27.7 to 17.0) | -16.0 (-21.4 to 10.6) | -3.1 (-8.2 to 2.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg QD | — | — | — |
| Sitagliptin 50 mg BID | — | — | — |
| Placebo | — | — | — |
| Event | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo |
|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 1/27 | 2/25 | 0/28 |
| Event | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/27 | 1/25 | 2/28 |
| Age, Continuous(years) | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 54.2 ± 8.9 | 56.1 ± 8.9 | 53.6 ± 10.3 | 54.6 ± 9.4 |
| Sex: Female, Male(Participants) | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo | Total |
|---|---|---|---|---|
| Female | 10 | 7 | 8 | 25 |
| Male | 17 | 18 | 20 | 55 |
| 24-hour weighted mean plasma glucose (24hr-WMG)(mg/dL) | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 195.0 ± 55.6 | 188.9 ± 46.6 | 195.4 ± 46.2 | 193.2 ± 49.1 |
| Fasting Plasma Glucose (FPG)(mg/dL) | Sitagliptin 100 mg QD | Sitagliptin 50 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 158.6 ± 41.0 | 156.4 ± 41.3 | 164.1 ± 36.9 | 159.9 ± 39.3 |
No study locations are listed for this record.
Ran from Jul 2005 to primary completion in Feb 2006, 7 months.
Results were first posted in Sep 2009, 3 years 7 months after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin